Le Lézard
Classified in: Health
Subject: FDA

Media Invitation - La Jolla, CA Medical Center, Achieve TMS, Unveils State-of-the-Art/FDA-Approved Neuro-Navigation System


SAN DIEGO, Aug. 5, 2019 /PRNewswire-PRWeb/ -- Achieve TMS, the nation's most trusted deep Transcranial Magnetic Stimulation (dTMS) provider, will begin offering treatments at its La Jolla center using a state-of-the-art and FDA-approved Neuro-Navigation system for patients with depression, OCD and other conditions.

This is the first such system available in San Diego. Achieve TMS will hold a demonstration event for interested media at 5:30 pm on Thursday August 8, 2019 at Achieve TMS La Jolla, located at 4510 Executive Drive, Suite 111, San Diego, 92121. Space is limited and advance notice is required via lsegall(at)achievetms.com.

The informative event will include an introduction and medical explanation of MRI-guided brain mapping neuro-navigation transcranial magnetic stimulation (TMS) system for treating major depressive disorder (MDD) and other treatment-resistant neuropsychiatric conditions. Achieve TMS La Jolla and Drs. Lindsay Oberman, Manish Sheth and Shashita Inamdar will lead the discussion.

MRI-guided neuro-navigation has been successfully used for over 20 years in complex neurosurgical procedures. Now, for the first time, this technology is available via Smart Focus TMS by Nexstim to provide ultra high precision TMS treatment of complex and treatment-resistant neuropsychiatric conditions such as depression, OCD, TBIs, Autism, Addictions and ADHD. This treatment option is now available at Achieve TMS La Jolla.

 

SOURCE Achieve TMS


These press releases may also interest you

at 07:35
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced updated data from two pivotal Phase III Venclexta® (venetoclax) studies (MURANO and CLL14) that highlight Venclexta combination treatments as chemotherapy-free,...

at 07:30
AbbVie , a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with VENCLEXTA®/VENCLYXTO® (venetoclax) in combination...

at 07:00
Intelligent.com, a trusted resource for online degree rankings and higher education planning, has announced the Top 27 Master's in History Degree Programs for 2020. The comprehensive research guide is based on an assessment of 155 accredited colleges...

at 07:00
Intelligent.com, a trusted resource for online degree rankings and higher education planning, has announced the Top 52 Best Homeland Security Degree Programs for 2020. The comprehensive research guide is based on an assessment of 116 accredited...

at 06:00
Intelligent.com, a trusted resource for online degree rankings and higher education planning, has announced the Top 50 Best Master's in Healthcare Administration Degree Programs for 2020. The comprehensive research guide is based on an assessment of...

7 déc 2019
Unlearn.AI, developer of the first machine-learning (ML) platform that creates Digital Twins to populate Intelligent Control Arms in clinical studies, today presented results generated from the company's latest Alzheimer's disease model at the...



News published on 5 august 2019 at 12:00 and distributed by: